Claims
- 1. An isolated, purified or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides selected from the group consisting of: nucleotide position range 213818 to 243685 of SEQ ID No. 1, SEQ ID Nos. 2 to 26 and 44 to 111, and the complements thereof.
- 2. An isolated, purified or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides selected from the group consisting of: SEQ ID Nos 36 to 40, SEQ ID Nos. 112 to 229, and nucleotide position ranges 31 to 292651 and 292844 to 319608 of SEQ ID No. 1, and the complements thereof.
- 3. An isolated, purified or recombinant polynucleotide according to claim 2, wherein said contiguous span of SEQ ID No 1 or the complements thereof comprises at least 1 of the following nucleotide positions of SEQ ID No 1:
(a) 292653 to 296047, 292653 to 292841, 295555 to 296047, and 295580 to 296047; (b) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854; (c) 94124 to 94964; (d) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and (e) 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915
- 4. An isolated, purified or recombinant polynucleotide according to claims 1 or 2, wherein said span comprises a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489.
- 5. A recombinant vector comprising a polynucleotide according to any one of claims 1 to 4.
- 6. A host cell comprising a recombinant vector according to claim 5.
- 7. A non-human host animal or mammal comprising a recombinant vector according to claim 5.
- 8. A mammalian host cell comprising an sbg1, g34665, sbg2, g35018 or g35017 gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1 or 3.
- 9. A non-human host mammal comprising an sbg1, g34665, sbg2, g35018 or g35017 gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1 or 3.
- 10. Use of a polynucleotide comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of the SEQ ID Nos 1 to 26, 36 to 40 and 112 to 229 or the complementary sequence thereto for determining the identity of the nucleotide at a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489.
- 11. A polynucleotide according to claim 10, wherein said polynucleotide consists essentially of a sequence selected from the group consisting of D1 to D69, D71 to D74, D76 to D94, D96 to D106, D108 to D112, D114 to D177, D179 to D197, D199 to D222, D224 to D246, D250, D251, D253, D255, D259, D266, D268 to D232 and D328 to D360.
- 12. A polynucleotide according to claim 2, consisting essentially of a sequence selected from the following sequences: B1 to B229, C1 to C229, and P1 to P69, P71 to P74, P76 to P94, P96 to P106, P108 to P112, P114 to P177, P179 to P197, P199 to P222, P224 to P246, P250, P251, P253, P255, P259, P266, P268 to P232 and P328 to P360.
- 13. Use of a polynucleotide comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of the SEQ ID Nos 1 to 26, 36 to 40 and 112 to 229 or the complementary sequence thereto for amplifying a segment of nucleotides comprising a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489.
- 14. A polynucleotide according to any one of claims 1 to 3 attached to a solid support.
- 15. A method of genotyping comprising determining the identity of a nucleotide at a Region D-related biallelic marker or the complement thereof in a biological sample.
- 16. A method of genotyping comprising determining the identity of a nucleotide at a biallelic marker selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A246, A250, A251, A253, A255, A259, A266, A268 to A232 and A328 to A489 or the complement thereof in a biological sample.
- 17. A method according to claim 16, wherein said determining comprises performing an assay selected from the group consisting of a hybridization assay, a sequencing assay, a microsequencing assay and a an enzyme-based mismatch detection assay.
- 18. A method of estimating the frequency of an allele of a biallelic marker in a population comprising:
a) genotyping individuals from said population for said biallelic marker according to the method of claim 16; and b) determining the proportional representation of said biallelic marker in said population.
- 19. A method of detecting an association between a genotype and a trait, comprising the steps of:
a) determining the frequency of at least one biallelic marker in trait positive population according to the method of claim 18;b) determining the frequency of at least one biallelic marker in a control population according to the method of claim 18; and c) determining whether a statistically significant association exists between said genotype and said trait.
- 20. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:
a) genotyping at least one biallelic marker according to claim 16 for each individual in said population; b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.
- 21. A method according to claim 20, wherein said haplotype determination method is selected from the group consisting of asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark method, or an expectation maximization algorithm.
- 22. A method of detecting an association between a haplotype and a trait, comprising the steps of:
a) estimating the frequency of at least one haplotype in a trait positive population according to the method of claim 21;b) estimating the frequency of said haplotype in a control population according to the method of claim 21; and c) determining whether a statistically significant association exists between said haplotype and said trait.
- 23. A method according to claim 19, wherein said genotyping of step a) is performed on each individual of said population.
- 24. A method according to claim 19, wherein said genotyping is performed on a single pooled biological sample derived from said population.
- 25. A method of detecting an association between an allele and a phenotype, comprising the steps of:
a) determining the frequency of at least one biallelic marker allele in a trait positive population according to the method of claim 18;b) determining the frequency of said biallelic marker allele in a control population according to the method of claim 18; and c) determining whether a statistically significant association exists between said allele and said phenotype.
- 26. A method according to claim 19 or 22, wherein said trait is schizophrenia or bipolar disorder.
- 27. A method according to claim 19 or 22, wherein said trait is predisposition to schizophrenia or bipolar disorder, an early onset of schizophrenia or bipolar disorder, or a beneficial response to or side effects related to treatment against schizophrenia or bipolar disorder.
- 28. A method of determining whether an individual is at risk of schizophrenia or bipolar disorder, comprising:
a) genotyping at least one biallelic marker according to the method of claim 16; and b) correlating the result of step a) with a risk of developing schizophrenia or bipolar disorder.
- 29. A purified or isolated sbg1 or g35018 polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 to 26 and 36 to 40, and fragments or variants thereof.
- 30. A purified or isolated sbg1 or g35018 polypeptide comprising at least 6 contiguous amino acid residues of any of SEQ ID Nos 27 to 25 and 41 to 43.
- 31. A purified or isolated sbg1 or g35018 polypeptide according to claim 30, comprising at least one amino acid substitution, addition or deletion.
- 32. A purified or isolated sbg1 peptide consisting essentially of an amino acid position range selected from the group consisting of:
1 to 63 and 64 to 102 of SEQ ID No 29; 1 to 64, 65 to 111 and 112 to 119 of SEQ ID No 30; 1 to 64 and 65 to 126 of SEQ ID No 32; 1 to 64, 65 to 123 and 124 to 153 of SEQ ID No 34; and 1 to 61 and 65 to 106 of SEQ ID No 35.
- 33. A method for producing an sbg1 or g35018 polypeptide, wherein said method comprises the following steps:
a) providing a cell host comprising a recombinant vector according to claim 5 containing a nucleic acid encoding an sbg1 or g35018 polypeptide; b) recovering the sbg1 or g35018 polypeptide produced by said recombinant cell host.
- 34. An isolated or purified antibody composition capable of selectively binding to a polypeptide according to any one of claims 30 to 32.
- 35. A method for specifically detecting the presence of an sbg1 or g35018 polypeptide in a biological sample, said method comprising the following steps:
a) bringing into contact the biological sample with an antibody directed against an sbg1 or g35018 polypeptide according to any one of claims 30 to 32; b) detecting the antigen-antibody complex formed between said antibody and said polypeptide.
- 36. A method for the screening of a candidate substance, wherein said method comprises the following steps:
a) providing a polypeptide according to anyone of claims 30 to 32; b) obtaining a candidate substance; c) bringing into contact said polypeptide with said candidate substance; d) detecting the complexes formed between said polypeptide and said candidate substance.
- 37. A method for the screening of a candidate substance, where said method comprises the following steps:
a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding an sbg1 protein or a variant or a fragment thereof, placed under the control of its own promoter; b) bringing into contact the cultivated cell with a molecule to be tested; c) quantifying the expression of the sbg1 protein or a variant or a fragment thereof.
- 38. A method for identifying a compound for the treatment of a disease, where said method comprises the following steps comprising:
(a) exposing an animal to a level of sbg1 activity sufficient to cause a schizophrenia-related or bipolar disorder-related symptom or endpoint, and (b) exposing said animal to a test compound.
- 39. A method according to claim 38, wherein said animal is a non-human mammal.
- 40. A method according to claim 38, wherein said animal is a non-human primate.
- 41. A method according to claim 38, wherein said animal is treated with an sbg1 polypeptide according to any one of claims 30 to 32.
- 42. A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:
a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 31 to 292651 and 292844 to 319608. b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 54 to 229, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID. c) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 2 to 26, 36 to 40, or the complements thereof. d) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1:
(i) 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047; (ii) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854; (iii) 94124 to 94964; (iv) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and (v) 201198 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915; e) a contiguous span according to a), b), c) or d), wherein said span includes a biallelic marker selected from the group consisting of A1 to A489. f) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one the ranges of nucleotide positions designated pos1 to pos166 of SEQ ID No. 1 listed in Table 1 above; g) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 40 and 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018-related biallelic marker; h) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos 2 to 26, 36 to 40 and 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q13-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018-related biallelic marker with the alternative allele present at said biallelic marker. i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and A361 to A489; j) a nucleotide sequence complementary to any one of the contiguous spans of a), b), c), d), e), f), g), h) and i).
- 43. A computer readable medium having stored thereon a sequence consisting of a polypeptide code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos. 27 to 35 and 41 to 43.
- 44. A computer system comprising a processor and a data storage device wherein said data storage device comprises a computer readable medium according to any one of claims 42 and 43.
- 45. A computer system according to claim 44, further comprising a sequence comparer and a data storage device having reference sequences stored thereon.
- 46. A computer system of claim 45 wherein said sequence comparer comprises a computer program which indicates polymorphisms.
- 47. A computer system of claim 45 further comprising an identifier which identifies features in said sequence.
- 48. A method for comparing a first sequence to a reference sequence, comprising the steps of:
a) reading said first sequence and said reference sequence through use of a computer program which compares sequences; and b) determining differences between said first sequence and said reference sequence with said computer program, wherein said first sequence is selected from the group consisting of a nucleic acid code comprising one of the following: (i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 31 to 292651 and 292844 to 319608. (ii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 54 to 229, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID. (iii) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 2 to 26, 36 to 40, or the complements thereof. (iv) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1:
a) 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047; b) 31 to 1107, 1108 to 65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854; c) 94124 to 94964; d) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and e) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915; (v) a contiguous span according to (i) to (iv), wherein said span includes a biallelic marker selected from the group consisting of A1 to A489. (vi) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one the ranges of nucleotide positions designated pos1 to pos166 of SEQ ID No. 1 listed in Table 1; (vii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 40, 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q13-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018-related biallelic marker; (viii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos 2 to 26, 36 to 40, 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q13-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018-related biallelic marker with the alternative allele present at said biallelic marker. (ix) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199 to A222, A224 to A242 and A361 to A489; (x) a nucleotide sequence complementary to any one of the contiguous spans of (i) to (ix); and (xi) a polypeptide code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos 27 to 35 and 41 to 43.
- 49. A method according to claim 48, wherein said step of determining differences between the first sequence and the reference sequence comprises identifying at least one polymorphism.
- 50. A method for identifying a feature in a sequence, comprising the steps of:
a) reading said sequence through the use of a computer program which identifies features in sequences; and b) identifying features in said sequence with said computer program; wherein said sequence is selected from the group consisting of a nucleic acid code comprising one of the following:
(i) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1, and the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 31 to 292651 and 292844 to 319608. (ii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 54 to 229, and the complements thereof, to the extent that such a length is consistent with the particular sequence ID. (iii) a contiguous span of at least 8, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 or 200 nucleotides, to the extent that such a length is consistent with the particular sequence ID, of SEQ ID Nos. 2 to 26, 36 to 40, or the complements thereof. (iv) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90 or 100 nucleotides of SEQ ID No. 1 or the complements thereof wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1:
a) 292653 to 296047, 292653 to 292841, 295555 to 296047 and 295580 to 296047; b)31 to 1107, 1108to65853, 1108 to 1289, 14877 to 14920, 18778 to 18862, 25593 to 25740, 29388 to 29502, 29967 to 30282, 64666 to 64812, 65505 to 65853 and 65854 to 67854; c) 94124 to 94964; d) 213818 to 215818, 215819 to 215941, 215819 to 215975, 216661 to 216952, 216661 to 217061, 217027 to 217061, 229647 to 229742, 230408 to 230721, 231272 to 231412, 231787 to 231880, 231870 to 231879, 234174 to 234321, 237406 to 237428, 239719 to 239807, 239719 to 239853, 240528 to 240569, 240528 to 240596, 240528 to 240617, 240528 to 240644, 240528 to 240824, 240528 to 240994, 240528 to 241685, 240800 to 240993 and 241686 to 243685; and e) 201188 to 216915, 201188 to 201234, 214676 to 214793, 215702 to 215746 and 216836 to 216915; (v) a contiguous span according to (i) to (iv), wherein said span includes a biallelic marker selected from the group consisting of A1 to A489. (vi) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of SEQ ID No. 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one the ranges of nucleotide positions designated pos1 to pos166 of SEQ ID No. 1 listed in Table 1; (vii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 40, 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018-related biallelic marker; (viii) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID Nos. 2 to 26, 36 to 40, 54 to 229, and the complements thereof, wherein said span includes a chromosome 13q31-q33-related biallelic marker, a Region D-related biallelic marker, an sbg1-, g34665-, sbg2-, g35017- or g35018-related biallelic marker with the alternative allele present at said biallelic marker. (ix) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of any of SEQ ID No 1, and the complements thereof, wherein said span includes a polymorphism selected from the group consisting of A1 to A69, A71 to A74, A76 to A94, A96 to A106, A108 to A112, A114 to A177, A179 to A197, A199, to A222, A224 to A242 and A361 to A489;
(x) a nucleotide sequence complementary to any one of the contiguous spans of (i) to (ix); and (xi) a polypeptide code comprising a contiguous span of at least 6 amino acids of a polypeptide sequence selected from the group consisting of SEQ ID Nos 27 to 35 and 41 to 43.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/416,384, filed Oct. 12, 1999. This application also claims priority to U.S. Provisional Patent Application Nos. 60/126,903, filed Mar. 30, 1999; 60/131,971, filed Apr. 30, 1999; 60/132,065, filed Apr. 30, 1999; 60/143,928, filed Jul. 14, 1999; 60/145,915, filed Jul. 27, 1999; 60/146,453, filed Jul. 29, 1999; 60/146,452, filed Jul. 29, 1999; and 60/162,288, filed Oct. 28, 1999. All of the above applications are hereby incorporated by reference in their entiretires.
Provisional Applications (8)
|
Number |
Date |
Country |
|
60126903 |
Mar 1999 |
US |
|
60131971 |
Apr 1999 |
US |
|
60132065 |
Apr 1999 |
US |
|
60143928 |
Jul 1999 |
US |
|
60145915 |
Jul 1999 |
US |
|
60146453 |
Jul 1999 |
US |
|
60146452 |
Jul 1999 |
US |
|
60162288 |
Oct 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09539333 |
Mar 2000 |
US |
Child |
10147603 |
May 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09416384 |
Oct 1999 |
US |
Child |
09539333 |
Mar 2000 |
US |